Pfizer discontinues phase 3 study of figitumumab in previously treated patients with advanced NSCLC
Saturday, March 13, 2010 14:00 IST New York
Pfizer Inc. announced the discontinuation of A4021018 (also known as ADVIGO 1018), a phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib
